Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Predictive factors of prostate cancer diagnosis with PSA 4.0-10.0 ng/ml in a multi-ethnic Asian population, Malaysia.
|
30962017 |
2020 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Seven hundred three (n = 703) prostate cancer (PCa) patients with confirmed PSA failure after radical therapy were enrolled.
|
31492993 |
2020 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to design and evaluate the value of prostate-specific membrane antigen (PSA)-targeted manganese oxide-mesoporous silica nanoparticles (Mn-Msns) for the detection of prostate cancer.
|
31731188 |
2020 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The differences in f/t PSA, PV, and PSAD for patients with and without PCa were statistically significant.(p < .001).
|
30862227 |
2020 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified the best cutoff values for prostate biopsy (0.25 for all prostate cancers and 0.20 for clinically significant prostate cancers) to determine whether to require prostate biopsy when the PSA level is in the diagnostic gray zone.
|
31169140 |
2020 |
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In both groups there was a curative intention to treat localized high-risk prostate cancer (one or more of Gleason score 8-10, PSA 20-50 or stage T3), diagnosed between 1995-2010, follow-up at the end of 2014.
|
30990112 |
2020 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA alone does not appear to be sufficient to detect the persistence of residual prostate cancer after radiotherapy.
|
31628565 |
2020 |
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We identified 6.509 patients with prostate cancer who had received hormonal therapy with a post-hormonal therapy PSA ≥2ng/mL, 363 of whom had non-metastatic, castrate-resistant prostate cancer.
|
31851457 |
2020 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, among 143 patients with PCa who received radical prostatectomy (RP), the AUCs of LDN-PSA, LDN-PSAD, and PSAD levels (0.750, 0.812, and 0.769, respectively) detected in patients with a pathologic Gleason grade group ≥ 2 were significantly higher (P = .0170, P = .0028, and P = .0003, respectively) than that of PSA (0.578).
|
31711843 |
2020 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this case report, a 67-year-old male with a history of prostate cancer status post prostatectomy presented for an F-18-fluciclovine PET/CT for a rising, clinically detectable PSA and indeterminate pelvic lymph nodes seen on multiparametric MRI of the prostate.
|
31715513 |
2020 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Risk-based patient selection for systematic biopsy in prostate cancer diagnosis has been adopted in daily clinical practice, either by clinical judgment and PSA testing, or using multivariate risk prediction tools.
|
31399825 |
2020 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Seminal citrate is superior to PSA for detecting clinically significant prostate cancer.
|
31808398 |
2020 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among subjects in a clinical trial with a prior negative biopsy, total PSA, free-PSA ratio and PSA density have comparable diagnostic characteristics for PCa screening in low and normal testosterone men.
|
31733275 |
2020 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
The resulting area under the receiver operating characteristic curve (AUC) to predict csPCa was 0.76 for PI-RADS v2, 0.59 for age, and 0.67 for PSA density.
|
31690449 |
2020 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Native American patients had higher PSA (8 ng/ml vs. 6.3 ng/ml), higher rate of D'Amico high-risk PCa (30.8 vs. 24.8%), higher rate of T3/T4-PCa (5.5 vs. 3.7%), higher rate of N1 stage (4.5 vs. 2.8%), and higher rate of M1 stage (7.5 vs. 3.9%, all p < 0.001) than CAP.
|
31695139 |
2019 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data suggest, that SRT administered at early PSA rise might be equieffective to postoperative ART in patients with locally advanced PC.
|
31711524 |
2019 |
Malignant neoplasm of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG-rearranged prostate cancer.
|
31090082 |
2019 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL.
|
31722940 |
2019 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a heavily pretreated population of men with mCRPC, pembrolizumab was associated with a ≥50% PSA decline in 17% (8/48) of men, including a dramatic ≥90% PSA response in 8% (4/48), two of whom harbored pathogenic LRP1b mutations suggesting that LRP1b mutations may enrich for PD-1 inhibitor responsiveness in prostate cancer.
|
31270961 |
2019 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum PSA levels in patients with prostate cancer and other 33 different types of diseases.
|
30905464 |
2019 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Peritoneal carcinomatosis in prostate cancer is extremely rare and has been described in only few cases with high PSA level, androgen deprivation, or in symptomatic patients.
|
30540597 |
2019 |
Malignant neoplasm of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A monocentric RP database was queried for patients initially diagnosed with T4 prostate cancer, considered primarily as inoperable because of a fixed mass defined by rectal examination in combination with high PSA level and/or large foci of biopsy confirmed undifferentiated prostate cancer.
|
29772100 |
2019 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, elevated serum ALCAM is indicative of progression and poorer patient outlook, and demonstrates comparable prognostic ability to PSA in terms of metastasis and prostate cancer survival.
|
31695844 |
2019 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Time to sTF of each group was analyzed and compared by Kaplan-Meier method and correlations regarding sTF and pre-sLND PSA, time from PCa primary treatment to PET/CT scan, time from PCa primary treatment to sLND and number of positive PET/CT scan spots were assessed.
|
30643974 |
2019 |
Malignant neoplasm of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
A multiplex model incorporating all the above genes and clinical information (PSA, age) identified patients with GG ≥ 2 PC (AUC 0.815, p < 0.0001).
|
31779677 |
2019 |